TXG
10x Genomics
--
--(--)
Market Open: --
--
--(--)
Post-Market: --
Signals Analysis
Buy signal 1
Sell signal 4
consensus rating "Strong Buy"
Downward Gap
Price Hits New Low
Price Hits 52-week low
Revenue Below Expectations
Key Stats
--DAY`S RANGE--
--52 WK RANGE--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
--
About TXG
10x Genomics, Inc.
A life sciences leader that develops instruments, consumables and software for analyzing biological systems complexity of biology
Life Science Tools and Services
07/02/2012
09/12/2019
NASDAQ Stock Exchange
1306
12-31
Common stock
6230 Stoneridge Mall Road, Pleasanton, California 94588
--
10x Genomics, Inc., was incorporated in Delaware on July 2, 2012. The Company started commercial and manufacturing operations and sales of its instruments and consumables in 2015. The company's integrated solutions include the company's Chromium instruments, its enzymes, reagents, microfluidic chips and other consumables, and software for analyzing biological systems.
Company Financials
EPS
TXG has released its 2024 Q4 earnings. EPS was reported at -0.40, versus the expected -0.11, missing expectations. The chart below visualizes how TXG has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
TXG has released its 2024 Q4 earnings report, with revenue of 165.02M, reflecting a YoY change of -10.30%, and net profit of -49.03M, showing a YoY change of -0.16%. The Sankey diagram below clearly presents TXG’s revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
